The strong operational beat and robust growth in Skyrizi/Rinvoq support the core thesis, but the Apogee acquisition introduces near-term dilution and integration risk. Monitor the Q3 close of the Apogee deal and any pipeline readouts for zumilokibart (APG777) that could validate the $10.9B price tag.
Drugs in focus
ABBV drug pipeline →Venclexta
● Neutral Named in this 8-K- Impact
- Phase
- Approved (marketed); supplemental/expansion trials Phase 3
- Time to market
- Already on the market — accelerated US approval 2016 (17p-deleted CLL), broader CLL/SLL approval 2019, AML approvals since 2018-2020, and newest first-line CLL combo approval February 2026.
- Next catalyst
- None dated
What to watchThe defining approvals are already in: Venclexta is a marketed CLL/AML franchise with a fresh US label expansion (first-line CLL combo, Feb 2026), so there is no pending PDUFA-style binary to trade, the next meaningful moves will come from quarterly hematology revenue commentary and competitive data from next-generation BCL-2 inhibitors (e.g., BeiGene's sonrotoclax). ABBV's stock is driven far more by its immunology portfolio (Skyrizi/Rinvoq) than by Venclexta, so position sizing should treat this drug as steady cash flow, not a swing factor.
- ◆ zumilokibart 4/10 Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026 Named in filing
- ● Aquipta 3/10 Approved (FDA approval 2021-09-28 per SecBot catalyst record); post-approval Phase 3 programs completed Named in filing
- ● Creon 3/10 Approved (FDA approved April 2009; marketed) Named in filing
- ● Decnupaz 3/10 Approved Named in filing
- ● Elahere 3/10 Unverified this session — external web search unavailable (zero results on all queries) and local FDA/trial databases co Named in filing
- 16 more · All ABBV drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $250.94entry
- T+1 · 4mo ago −2.33%α −3.75% · $245.10
- T+5 · 3mo ago −1.95%α −5.46% · $246.04
- T+20 · 3mo ago +1.81%α −1.18% · $255.48
- T+60 · 22d ago +14.27%α +11.81% · $286.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AbbVie reported Q2 2026 adjusted EPS of $3.65, a 1.2% beat vs. consensus of $3.61, on revenue of $16.99B (above $16.76B consensus, +10.2% YoY). The company announced a definitive agreement to acquire Apogee Therapeutics for ~$10.9B and slightly lowered its full-year adjusted EPS guidance to $13.87-$14.07 to reflect the deal's $0.14 dilutive impact, partially offset by $0.10 of operational overperformance. Strong growth in immunology (Skyrizi +24.4%, Rinvoq +24.5%) and neuroscience (+20.3%) continues to offset Humira erosion (-35.9%).
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS $3.65 vs. consensus $3.61 (+1.2% beat)
- Q2 2026 revenue $16.99B vs. consensus $16.76B (+10.2% YoY reported)
- Announced definitive agreement to acquire Apogee Therapeutics for ~$10.9B equity value
- Full-year 2026 adjusted EPS guidance narrowed to $13.87-$14.07 from $13.91-$14.11 (includes $0.14 Apogee dilution)
- Skyrizi revenue $5.505B (+24.4% YoY); Rinvoq $2.525B (+24.5% YoY); Humira $756M (-35.9% YoY)
- Neuroscience revenue $3.228B (+20.3% YoY); Aesthetics $1.282B (+0.3% YoY)
- Adjusted operating margin expanded to 48.3% from 46.7% in Q2 2025
Financial Impact
Adjusted EPS beat by $0.04 (+1.2%) vs consensus; revenue beat by ~$230M (+1.4%) vs consensus; $10.9B acquisition announced
Risk Factors
- Apogee acquisition integration risk and $0.14 EPS dilution in 2026
- Continued Humira erosion (-35.9% YoY) and potential biosimilar competition
- Oncology portfolio decline (-1.5% YoY) and Imbruvica erosion (-29.4%)
- Aesthetics portfolio stagnation (+0.3% YoY) with Juvederm decline (-6.0%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000023 |
| Document: abbv-20260731.htm | 0001551152-26-000023 |
| Document: 0001551152-26-000023-index-headers.html | 0001551152-26-000023 |
| Document: 0001551152-26-000023-index.html | 0001551152-26-000023 |
| Document: 0001551152-26-000023.txt | 0001551152-26-000023 |
| 8-K Data (Synthetic) | 0001551152-26-000023 |
Track record
22 reports on ABBV
6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
- Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
- Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
- Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers